natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT NovoNorm 2 mg tablets Repaglinide 
NovoNorm 2 mg tablete repaglinid
NAME OF THE MEDICINAL PRODUCT NovoNorm 1 mg tablets Repaglinide 
NovoNorm 1 mg tablete repaglinid
EU/1/98/076/004 30 tablets EU/1/98/076/005 90 tablets EU/1/98/076/006 120 tablets EU/1/98/076/023 270 tablets 
EU/1/98/076/005 90 tablet EU/1/98/076/006 120 tablet
What you need to know before you take NovoNorm 
Kaj morate vedeti, preden boste vzeli zdravilo NovoNorm Ne jemljite zdravila NovoNorm, če:
NovoNorm tablets are round and convex and engraved with the Novo Nordisk logo (Apis bull). 
Izgled zdravila NovoNorm in vsebina pakiranja Tablete NovoNorm so okrogle in izbočene ter imajo vrezan logo družbe Novo Nordisk (bik Apis).
Repaglinide tablets are peach-coloured, round and convex and engraved with Novo Nordisk logo (Apis bull). 
Tablete repaglinida so breskove barve, okrogle, izbočene in imajo vrezan logo družbe Novo Nordisk
Eight percent of one dose of repaglinide is excreted through the kidneys and total plasma clearance of the product is decreased in patients with renal impairment. 
Repaglinid se hitro absorbira iz prebavil, zato se koncentracija zdravilne učinkovine v plazmi hitro zveča.
(cannot be estimated from the available data). 
(predprandialno odmerjanje).
Relative potency (R.P.) 
Relativna potenca (R.P.)
Revaccination: one vaccination annually. 
Re-vakcinacija: eno cepljenje na leto.
ATC vet code: QI06AL01. 
Oznaka ATC vet: QI06AL01.
Date of last renewal: 27 February 2007. 
Datum zadnjega podaljšanja dovoljenja za promet: 27. februar 2007.
Adjuvant: mineral oil. 
Dodatek: mineralno olje.
Vaccination of FeLV positive cats is of no benefit. 
Cepljenje FeLV pozitivnih mačk nima nobenih koristi.
Eagles Earles Medium with Hepes 
Eagles Earles medij s Hepesom
Emulsigen SA 
Emulgator SA
Accidental injection is dangerous. 
Namerno injiciranje je nevarno.
Ethylene/maleic anhydride (EMA-31) Neocryl 
Etilen/maleinski anhidrid (EMA-31) Neokril
Vaccine appearance is a pale milky pink liquid which should be free from solid particles. 
Cepivo ima videz bledo mlečne roza tekočine, ki bi morala biti brez trdih delcev.
The syringes are sealed with rubber tips. 
Brizga je zaprta z gumijastim pokrovčkom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 5 February 1997. 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 5. februar 1997.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis. 
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
EXPIRY DATE EXP {month/year} 
EXP{ mesec/leto}
Basic vaccination of cats 9 weeks and older: two doses at an interval of 3 to 4 weeks. 
Osnovno cepljenje mačk, starih 9 tednov in več: dva odmerka v intervalu 3 do 4 tednov.
Incompatibilities: Do not mix with any other veterinary medicinal product. 
Inkompatibilnosti: Ne mešajte z nobenim drugim zdravilom.
Any unused product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with national requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
Pharmacotherapeutic group: immunologicals for felidae, inactivated viral and inactivated bacterial vaccines for cats. 
Farmakoterapevtska skupina: Imunološka sredstva za felidae, inaktivirana virusna in inaktivirana bakterijska cepiva za mačke.
Vaccinated cats may develop post-vaccinal reactions including transient fever, vomiting, anorexia and/or depression which usually disappear within 24 hours. 
Zelo redko se lahko po cepljenju pojavijo reakcije kot so povišana telesna temperatura, bruhanje, anoreksija in/ali depresija, ki običajno izginejo v 24 urah.
Test negative animals can be vaccinated, while test-positive cats should be isolated from other cats and retested within 1-2 months. 
Mačke, ki so bile po testiranju negativne, se lahko cepijo, pozitivne pa se izolirajo od ostalih in ponovno testirajo čez 1-2 meseca.
Cats negative at second testing can be vaccinated since, in all likelihood, they have overcome the FeLV infection. 
Mačke, ki pa so po drugem testiranju negativne, se lahko cepi, saj so po vsej verjetnosti v tem času že prebolele FeLV infekcijo.
If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. 
Če vam je bilo to zdravilo nenamerno injicirano, se takoj posvetujte z zdravnikom, čeprav je bila injicirana le majhna količina in mu pokažite navodila za uporabo.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years. 
6.3 Rok uporabnosti Rok uporabnosti zdravila v pakiranju za prodajo: 2 leti.
In case of anaphylactoid reaction, adrenaline should be administered intramuscularly. 
V primeru anafilaktoidne reakcije se aplicira adrenalin intramuskularno.
No undesirable effects other than those observed and mentioned in section 4.6 “Adverse reactions” have been observed. 
Tudi preveliki odmerki niso povzročili nobenih drugih neželenih učinkov, kot tistih, ki so navedeni v poglavju 6 " Neželeni učinki".
See section 4.5 for guidance about treatment. 
Za navodila glede zdravljenja, glejte poglavje 4.5.
See section 4.4 for further details. 
Za podrobne podatke, glejte poglavje 4.4.
Cats positive at the second testing should be considered as being permanently infected with FeLV and should be handled accordingly. 
Mačke, ki so tudi po drugem testiranju pozitivne, se tretira kot stalno okužene s povzročitelji FeLV in se z njimi ustrezno ravna.
It is therefore recommended that cats with a significant risk of having been exposed to FeLV be tested for FeLV antigen prior to vaccination. 
Zato se priporoča, da mačke, pri katerih obstaja tveganje, da so bile izpostavljene FeLV, pred cepljenjem testiramo na prisotnost FeLV antigenov.
Name and address of the manufacturers of the biological active substances 
Ime in naslov proizvajalca (proizvajalcev) biološke (bioloških) učinkovine (učinkovin)
Overdose (symptoms, emergency procedures, antidotes): No undesirable effects other than those mentioned in section 6 have been observed. 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), (če je potrebno) Tudi preveliki odmerki niso povzročili nobenih drugih neželenih učinkov, kot tistih, ki so navedeni v poglavju 4.6 " Neželeni učinki".
An additional dose is recommended for kittens living in high-risk FeLV environments whose first dose was administered before 12 weeks of age. 
Priporoča se še dodaten odmerek za mačje mladiče, ki živijo v visoko rizičnem FeLV okolju, če so prvi odmerek cepiva dobili pred 12 tedni starosti.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only. 
BESEDILO ˝SAMO ZA ŽIVALI˝ Samo za živali.
An additional dose is recommended for kittens living in high-risk feline leukaemia virus (FeLV) environments whose first dose was administered before 12 weeks of age. 
Priporoča se še dodaten odmerek za mačje mladiče, ki živijo v visoko rizičnem okolju za virus mačje levkemije (FeLV), če so prvi odmerek cepiva dobili pred 12 tedni starosti.
QUANTITY OF THE ACTIVE SUBSTANCE(S) FPV / FCV / FVR / Chlam / FeLV 
FPV / FCV / FVR / Chlam / FeLV
In very rare cases an anaphylactoid reaction with oedema, pruritis, respiratory and cardiac distress, severe gastrointestinal signs or shock has been seen during the first hours after vaccination. 
Zelo redko se lahko v nekaj urah po cepljenju pojavi anafilaktoidna reakcija, ki jo spremlja edem, srbenje, motnje v delovanju srca in dihal, resne gastrointestinalne motnje ali šok.
QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml (single dose syringe): 
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 odmerek po 1 ml (enoodmerna brizga) vsebuje: Učinkovine
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Per dose of 1 ml (single dose syringe): 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SESTAVIN 1 odmerek po 1 ml (enoodmerna brizga) vsebuje:
When administering the product, care must be taken to attach the enclosed sterile needle aseptically to the syringe before use. 
Pred uporabo cepiva je potrebno na brizgo aseptično namestiti priloženo sterilno iglo.
10 x 1 ml single dose syringes 20 x 1 ml single dose syringes 25 x 1 ml single dose syringes 
VELIKOST PAKIRANJA 10 x 1 ml enoodmerna brizga 20 x1 ml enoodmerna brizga 25 x1 ml enoodmerna brizga
Special precautions to be taken by the person administering the veterinary medicinal product to animals: 
Posebni varnostni ukrepi, ki jih mora izvajati oseba, ki daje zdravilo živalim:
Single dose disposable Type I glass syringes containing one dose (l ml) of vaccine. 
Enoodmerna brizga za enkratno uporabo iz stekla tipa I, napolnjena z 1 ml cepiva.
For the active immunisation of healthy cats 9 weeks or older against feline panleucopenia and feline leukaemia viruses and against respiratory diseases caused by feline rhinotracheitis virus, feline calicivirus and Chlamydophila felis. 
Aktivna imunizacija zdravih mačk, starih 9 tednov ali več proti mačji panleukopeniji in mačji leukemiji ter proti respiratornim boleznim, ki jih povzročajo virusi mačjega rinotraheitisa, mačji calicivirusi in mačja
One cardboard box containing 10, 20 or 25 single dose (1 ml) pre-filled syringes and 10, 20 or 25 sterile needles respectively. 
Kartonska škatla z 10 ali 20 ali 25 napolnjenimi enoodmernimi brizgami po 1 ml cepiva in s priloženimi 10, 20 ali 25 sterilnimi iglami.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE Veterinary medicinal product subject to prescription. 
B POGOJI TER OMEJITVE GLEDE OSKRBE IN UPORABE Na veterinarski recept.
Do not mix with any other veterinary medicinal product. 
6.2 Glavne inkompatibilnosti Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini.
Fevaxyn Pentofel stimulates the development of active immunity against feline panleucopenia virus, feline rhinotracheitis virus, feline calicivirus, Chlamydophila felis and feline leukaemia virus. 
Cepivo stimulira nastanek aktivne imunosti proti virusom mačje panleukopenije, mačjega rinotraheitisa, mačjim calicivirusom, Chlamydophila felis.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 1 ml. 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
A local reaction with swelling, pain, pruritis or hair loss at the injection site may be observed. 
Včasih se na mestu cepljenja pojavi oteklina, bolečina, srbenje ali izguba dlake.
Vaccination does not affect the course of feline leukaemia virus (FeLV) infection in cats already infected with FeLV at the time of vaccination, implying that such cats will excrete FeLV irrespective of vaccination; consequently, these animals will constitute a hazard to susceptible cats in their environment. 
Cepljenje nima učinka na potek infekcije z virusom mačje levkemije (FeLV) pri mačkah, ki so v času cepljenja že okužene s povzročitelji FeLV.
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
PARTICULARS TO APPEAR ON THE OUTER PACKAGE BOX OF 10 x 1 ML SINGLE DOSE SYRINGES, 20 x 1 ML SINGLE DOSE SYRINGES , 25 x 1 ML SINGLE DOSE SYRINGES 
ŠKATLA 10 X 1 ML ENOODMERNA BRIZGA, 20 X 1 ML ENOODMERNA BRIZGA, 25 X 1 ML ENOODMERNA BRIZGA
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SINGLE DOSE SYRINGE 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Adjuvants 
Učinkovine
25 x 1 ml presentation: Box containing 25 single dose prefilled syringes and 25 sterile needles. 
25 x 1 ml pakiranje: kartonska škatla z 25 napolnjenimi enoodmernimi brizgami in z 25 sterilnimi iglami.
The contents of the single dose syringe should be shaken well and administered aseptically by subcutaneous injection. 
NASVET O PRAVILNI UPORABI ZDRAVILA Vsebino enoodmerne brizge pred uporabo pretresemo in apliciramo subkutano.
Inactivated feline panleucopenia virus, strain CU4 Inactivated feline calicivirus, strain 255 
Inaktiviran mačji calicivirus, sev 255
20 x 1 ml presentation: Box containing 20 single dose prefilled syringes and 20 sterile needles. 
20 x 1 ml pakiranje: kartonska škatla z 20 napolnjenimi enoodmernimi brizgami in z 20 sterilnimi iglami.
NAME OF THE VETERINARY MEDICINAL PRODUCT Fevaxyn Pentofel suspension for injection for cats 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Fevaxyn Pentofel suspenzija za injiciranje za mačke
10 x 1 ml presentation: Box containing 10 single dose prefilled syringes and 10 sterile needles. 
10 x 1 ml pakiranje: kartonska škatla z 10 napolnjenimi enoodmernimi brizgami in z 10 sterilnimi iglami.
PACKAGE LEAFLET: Fevaxyn Pentofel, suspension for injection for cats 
NAVODILO ZA UPORABO Fevaxyn Pentofel, suspenzija za injiciranje za mačke
The safety of the vaccine in pregnant queens has not been investigated. 
Nosečnost: Varnost cepiva pri brejih mačkah ni bila raziskana, zato se ne priporoča cepljenja brejih mačk.
Vaccination does not affect the course of FeLV infection in cats already infected with FeLV at the time of vaccination, implying that such cats will excrete FeLV irrespective of vaccination; consequently, these animals will constitute a hazard to susceptible cats in their environment. 
Te mačke izločajo FeLV ne glede na cepljenje in predstavljajo veliko nevarnost kot vektor okužb v okolju za druge mačke.
Inactivated feline rhinotracheitis virus, strain 605 Inactivated Chlamydophila felis, strain Cello Inactivated feline leukaemia virus, strain 61E 
Inaktiviran virus mačjega rinotraheitisa, sev 605
NAME OF THE VETERINARY MEDICINAL PRODUCT Fevaxyn Pentofel for cats 
Fevaxyn Pentofel za mačke
Subcutaneous use. 
Odmerek znaša 1 ml. Subkutana uporaba.
50 mg Film-coated tabletOral use blister (alu/alu) 
50 mg filmsko obložene tablete peroralna uporaba pretisni omot (aluminij/aluminij)
Strength Pharmaceutical Form 
Jakost Farmacevtska oblika Pot uporabe Stična ovojnina Velikost pakiranja
2 These are medicinal products within class where similar interactions could be predicted. 
2 To so zdravila znotraj razreda, kjer je mogoče predvideti podobne interakcije.
This may become severe or potentially life-threatening. 
To lahko postane resno ali potencialno življenjsko nevarno.
A nutritional drink alone does not replace food. 
Samo hranljivi napitek ne nadomesti hrane.
Where possible, alternatives such as azithromycin should be considered. 
Kjer je možno, je treba razmisliti o alternativnih zdravilih, kot je azitromicin.
• If you are currently taking any of the following medicines 
• Če trenutno uporabljate katero koli od naslednjih zdravil
a Week 24 window is between day 127 and 210 (inclusive). 
a Okno v 24. tednu je med 127. in 210. dnevom (vključno z njima).
ATC code: J05AR08. 
Oznaka ATC: J05AR08.
The virus may then become harder to treat. 
Nato bo morda virus še težje zdraviti.
If you are taking rifabutin. 
Če jemljete rifabutin.
This is important to get the right levels of active substance in your body. 
To je pomembno, da dobite pravilne ravni učinkovine v telo.
Cimetidine2 Nizatidine2 Ranitidine2 
cimetidin2 nizatidin2 ranitidin2
Talk to your doctor about an alternative regimen. 
Z zdravnikom se pogovorite o alternativnem režimu.
Resistance to tenofovir (K65R) 
Rezistenca na tenofovir (K65R)
Demographic Characteristics Median age (range), years 
Demografske značilnosti Mediana starost (razpon), leta
• Depression and depressed mood 
• depresija in depresivno razpoloženje
See section 4.8, Description of selected adverse reactions. 
Glejte poglavje 4.8, Opis izbranih neželenih učinkov.
Alternatively, switching to another antiretroviral regimen could be considered. 
Druga možnost je, da se razmisli o prehodu na drug protiretrovirusni režim.
Pregnant women should not take Eviplera unless you and your doctor decide it is clearly needed. 
Noseče ženske ne smejo jemati zdravila Eviplera, razen če ste se vi in vaš zdravnik odločili, da je to nujno potrebno.
This should be considered when assessing a patient's ability to drive or operate machinery. 
To je treba upoštevati pri ocenjevanju bolnikove sposobnosti vožnje ali upravljanja strojev.
Non-response Virologic failure (all patients) 
Neodzivni Virološki neuspeh (vsi bolniki)
Virologic failure and development of resistance 
Virološki neuspeh in razvoj rezistence
In patients with phenotypic data (n = 66) 
Pri bolnikih s fenotipskimi podatki (n = 66)
• Antibiotics used to treat bacterial infections including tuberculosis containing: 
• Antibiotiki, ki se uporabljajo za zdravljenje bakterijskih okužb, vključno s tuberkulozo, ki vsebujejo:
This, will improve your immune system and reduces the risk of developing illnesses linked to HIV infection. 
S tem se vaš imunski sistem izboljša in zmanjša se tveganje za razvoj bolezni, povezanih z okužbo s HIV.
• This is because the active substances in this medicine pass into human breast milk. 
• To je zato, ker učinkovine tega zdravila prehajajo v materino mleko.
Effects on electrocardiogram 
Učinki na elektrokardiogram
Tenofovir concentrations not measured, no effect is expected. 
Koncentracij tenofovira niso merili, učinkov se ne pričakuje.
 Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection. 
 Nemudoma obvestite zdravnika o vsakem novem ali nenavadnem simptomu potem, ko ste prenehali z zdravljenjem, še posebej o simptomih, ki jih povezujete z okužbo s hepatitisom B.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available. 
Nadaljnje zdravljenje mora potekati, kot je klinično indicirano ali v skladu s priporočili nacionalnega centra za zastrupitve, če je na voljo.
Your doctor may need to give you an additional dose of rilpivirine. 
Vaš zdravnik vam bo morda moral dati dodatni odmerek rilpivirina.
Interaction studies with these active substances have only been performed in adults. 
Študije medsebojnega delovanja s temi učinkovinami so izvedli le pri odraslih.
Treatment outcomes through 24 weeks are presented in Table 7. 
Izidi zdravljenja do konca 24. tedna so predstavljeni v preglednici 7.
Virologic success after 24 weeks of treatmentb 
Virološki uspeh po 24. tednih zdravljenjab
• Any other medicines containing: 
• Katero koli drugo zdravilo, ki vsebuje:
Your doctor may need to change the dose of the antibiotic or give you a different antibiotic. 
Vaš zdravnik bo morda moral spremeniti odmerek antibiotika ali vam dati drugi antibiotik.
• Tell your doctor immediately if you become pregnant or if you plan to become pregnant. 
• Zdravnika takoj obvestite, če zanosite ali če načrtujete zanositev.
Your doctor will discuss the potential benefits and risks of taking Eviplera to you and your child. 
Vaš zdravnik se bo z vami pogovoril o možnih koristih in tveganjih zdravljenja z zdravilom Eviplera za vas in vašega otroka.
In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) is similar to those seen in adults. 
Na splošno so farmakokinetične lastnosti emtricitabina pri dojenčkih, otrocih in mladostnikih (v starosti od 4 mesecev do 18 let) podobne tistim, ki so bile opažene pri odraslih.
Wait and take the next dose, with food, at your usual time. 
Počakajte in vzemite naslednji odmerek s hrano ob vašem običajnem času.
Eviplera reduces the amount of HIV in your body. 
Zdravilo Eviplera zmanjša količino virusa HIV v vašem telesu.
If you are over 65 years of age and are prescribed Eviplera, your doctor will monitor you carefully. 
Če ste stari več kot 65 let in so vam predpisali zdravilo Eviplera, vas bo zdravnik skrbno nadziral.
If you have hepatitis B, your doctor will carefully consider the best treatment regimen for you. 
Če imate hepatitis C, bo zdravnik natančno preučil najboljši režim zdravljenja za vas.
In vitro binding of rilpivirine to human plasma proteins is approximately 99.7%, primarily to albumin. 
In vitro vezava rilpivirina na humane plazemske proteine je približno 99,7 %, primarno na albumin.
Date of first authorisation: 28 November 2011 Date of latest renewal: 22 July 2016 
Datum zadnjega podaljšanja: 22. julij 2016
The absolute bioavailability of emtricitabine from 200 mg hard capsules was estimated to be 93%. 
Absolutna biološka uporabnost emtricitabina iz 200 mg trde kapsule je bila ocenjena s 93 %.
Interrupting treatment with Eviplera should also be considered in case of progressive decline of renal function when no other cause has been identified. 
O prekinitvi zdravljenja z zdravilom Eviplera je treba razmisliti tudi v primeru progresivnega upada ledvične funkcije, če ni bil ugotovljen noben drug razlog.
increased bilirubin1, 2 
zvišanje bilirubina1, 2
There were no new cross-resistance patterns at week 96 compared to week 48. 
Novih vzorcev navzkrižne rezistence v 96. tednu v primerjavi z 48. tednom ni bilo.
• If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
• Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
For the resistance analyses, a broader definition of virologic failure was used than in the primary efficacy analysis. 
Za analizo rezistence so uporabili širšo opredelitev virološkega neuspeha kot za analizo primarne učinkovitosti.
• Medicines that may damage your kidneys, examples include: 
• Zdravila, ki lahko poškodujejo ledvice, primeri vključujejo:
Decreases in BMD of hip were significantly greater in this group until 96 weeks. 
Zmanjšanje BMD v kolku je bilo do 96 tednov pomembno večje v tej skupini.
• Swelling of the face, lips, tongue or throat 
• oteklost obraza, ustnic, jezika ali grla
3 Phenotypic resistance (Antivirogram). 
2 Fenotipska rezistenca (Antivirogram).
Stopping Eviplera can seriously affect your response to future treatment. 
Prenehanje jemanja zdravila Eviplera lahko resno vpliva na vaš odziv na prihodnje zdravljenje.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, 17% were Black, and 17% were Hispanic/Latino. 
Bolniki so bili povprečno stari 42 let (razpon 19-73), 88 % je bilo moških, 77 % je bilo belcev, 17 % je bilo črncev in 17 % jih je bilo španskega/latinskoameriškega porekla.
Your doctor will carefully consider whether to treat you with other medicines used for treating HIV infection (see Other medicines used for HIV infection). 
Vaš zdravnik bo skrbno pretehtal, če vas bo zdravil z drugimi zdravili za zdravljenje okužb s HIV (glejte Druga zdravila, ki se uporabljajo za okužbe z virusom HIV).
No virologic data in week 24 window 
V oknu 24. tedna ni viroloških podatkov
• Deep, rapid breathing 
• globoko, hitro dihanje
Concomitant use where caution is recommended 
Sočasna uporaba, pri kateri je potrebna pazljivost
There are no adequate and well-controlled studies of Eviplera or its components in pregnant women. 
Ni zadostnih in dobro nadzorovanih študij zdravila Eviplera ali njegovih sestavin pri nosečnicah.
Eviplera has no or negligible influence on the ability to drive and use machines. 
Zdravilo Eviplera nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The combination of Eviplera and dabigatran etexilate should be used with caution. 
Kombinacijo zdravila Eviplera in dabigatran eteksilata je treba uporabljati previdno.
What Eviplera is and what it is used for 
Kaj je zdravilo Eviplera in za kaj ga uporabljamo
• interleukin-2, also called aldesleukin (to treat cancer) 
• interlevkin-2, imenuje se tudi aldeslevkin (za zdravljenje raka)
This includes medicines and herbal medicines obtained without a prescription. 
To velja tudi za zdravila in zeliščne pripravke, ki ste jih dobili brez recepta.
 Tell your doctor if you are taking any of these medicines. 
 Obvestite zdravnika, če jemljete katerega od teh zdravil.